复方樟柳碱联合长春胺治疗原发性缺血性视神经视网膜脉络膜病变疗效观察  

Curtive Effect Observation of Compound Anisodine and Vinpocetine on Primary Ischemic Optic Neuropathy and Chorioretinopathy

作　　者：张倩[1] 刘艳[1] 夏江南[1] 

机构地区：[1]武警湖北总队医院眼科,湖北武汉430061

出　　处：《医学新知》2012年第1期34-35,共2页New Medicine

摘　　要：目的观察复方樟柳碱联合长春胺注射液对原发性缺血性视神经视网膜脉络膜病变的疗效和安全性。方法按治疗方法将原发性缺血视神经视网膜脉络膜病变80例随机分为对照组（40例40眼）、治疗组（40例40眼）。对照组采用复方樟柳碱2ml患眼颞浅动脉旁注射；治疗组在对照组治疗方法的基础上应用长春胺注射液20mg加到0．9％生理盐水250ml中，静滴，1次／d。疗程均为20d。结果治疗组有效率为85％，对照组为70．0％，两者比较，差异有显著性（P〈0．05）。结论复方樟柳碱联合长春胺注射液治疗原发性缺血性视神经视网膜脉络膜病变的疗效较单独应用复方樟柳碱疗效更好且安全。Objective To investigate the treatment effect of compound anisodine and vinpocetine injection on primary ischemic optic neuropathy and chorioretinopathy and its safety. Methods A randomized and controlled study was applied to 80 patients with primary ischemic optic neuropathy and chorioretinopathy. Patients were assigned into two groups at random ：40 patients in control group and the other 40 ones in trial group. The trial group was treated with 2 ml compound ansiodine injected subcutaneously around superficial temporal artery and Vinpocetine （2 ml） injected once per day for 20 days, while the control group only treated with compound ansiodine at same day. Visual acuity, visual field and fuudus condition were examined so that the effect of treatment could be evaluated. The safety of the treatment was studied via intraocular pressure, blood pressure, electrocardiogram, routine blood and urine examination, and blood tests for renal and liver function. The main subjects of the two groups before treatment were comparable （ P 〉 0.05 ）. Results The difference in effective rate between trial group（85.0% ） and control group （ 70.0% ） was significant （ P 〈 0.05 ）. Conclusion Compound anisodine and vinpocetine is safe and effective to treat primary ischemic optic neuropathy and chorioretinopathy.

关 键 词：视神经疾病 脉络膜缺血性病变 复方樟柳碱 长春胺 

分 类 号：R774.1[医药卫生—眼科] R774.6[医药卫生—临床医学]